Clinical trials: Residual Disease
Multiple Myeloma (MM)
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Multiple myeloma is a type of blood cancer that can come back even after effective treatment. After high-dose therapy and autologous stem cell transplantation (ASCT), some patients have no visible signs of disease, but small…
- Trial name
- TiTan (NCT07740486)
- Testing
- Teclistamab, Talquetamab, Daratumumab (Subcutaneously)
- Volunteers
- 248 people
- Sponsor
- Polish Myeloma Consortium
Acute Lymphoblastic Leukemia, B-precursor
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether short-term blinatumomab intensification before allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival…
- Trial name
- NCT07003737
- Testing
- Blinatumomab, Consolidation Chemotherapy or Direct Allogeneic HSCT
- Where
- China
- Volunteers
- 114 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Chronic Kidney Disease, Diabetic Nephropathy
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Prospective, randomized, double-blind, placebo controlled, 12-week, multicenter study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets compared to placebo in…
- Trial name
- NCT01424319
- Testing
- Atrasentan low dose group, Atrasentan high dose group
- Where
- 18 sites in Japan
- Volunteers
- 58 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Amblyopia, Amblyopia Unilateral
Valproate for the Treatment of Residual Amblyopia
The goal of this clinical trial is to determine the efficacy of valproate as an adjunct therapy to treat amblyopia beyond the critical period in children aged 8-17 years who have amblyopia of ≥3 lines of interocular…
- Conditions
- Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
- Trial name
- VARA (NCT07226141)
- Testing
- Valproate, Patch
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Boston Children's Hospital
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of combining bryostatin 1 and cisplatin in treating patients who have advanced recurrent or residual ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00006942
- Testing
- bryostatin 1, cisplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Chronical Kidney Disease, Hypotension
Prediction of Risk of Hypotension in Hemodialysis
The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess…
- Conditions
- Chronical Kidney Disease, Hypotension, Residual Blood Volume, Hemodialysis
- Trial name
- IMHOTEP (NCT03350308)
- Testing
- hemodialysis
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Clermont-Ferrand
Psoriasis Vulgaris, Psoriasis
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
Psoriasis is a non-communicable chronic immune-mediated disease. Psoriatic skin is characterized by excessive proliferation of skin cells and infiltration of immune cells. The cause of psoriasis is so far unknown.
- Conditions
- Psoriasis Vulgaris, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- MEMPSOLAR (NCT05185258)
- Testing
- Enstilar
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aarhus University Hospital
Breast Cancer, Triple Negative Breast Cancer
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
- Trial name
- PERSEVERE (NCT04849364)
- Testing
- Capecitabine, Talazoparib, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Bryan Schneider, MD
Refractive Errors
Early Feasibility Study to Evaluate the AccuraSee in Correcting Residual Refractive Errors After Cataract Surgery
To determine if the intraocular pseudophakic contact lens (IOPCL), referred to as the AccuraSee, corrects residual refractive errors after cataract surgery using a plus powered lens in subjects with ocular pathology previously…
- Trial name
- NCT05113979
- Testing
- AccuraSee IOPCL with +3.0D add
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OnPoint Vision Inc
B-cell Acute Lymphoblastic Leukemia
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before…
- Trial name
- NCT03509961
- Testing
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Where
- 24 sites in United States
- Volunteers
- 95 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
Lymphocytic Leukemia
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
The purpose of this study is to assess the therapeutic efficacy of mosunetuzumab, a bispecific antibody targeting CD20 and CD3 in patients who have detectable chronic lymphocytic leukemia (CLL) after receiving Bruton's tyrosine…
- Trial name
- NCT07566364
- Testing
- Mosunetuzumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Obesity, Non-diabetic Chronic Kidney Disease
SGLT2 Inhibitors in Glomerular Hyperfiltration
Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with blood pressure and blood glucose (in…
- Trial name
- EMPATHY (NCT04143581)
- Testing
- Empagliflozin 10 MG
- Sponsor
- Mario Negri Institute for Pharmacological Research
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Osteoporosis
The Relationship Between the Residual Renal Function and Osteoporosis Treatment
The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.
- Trial name
- NCT02304887
- Testing
- Bis, SERM Teriparatide, Denosumab
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Toshihiko Kono
Cerebrovascular Disorders, Stroke
Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims
Background: Stroke represents one of the major health problems worldwide, particularly in transitional and industrialized countries.
- Conditions
- Cerebrovascular Disorders, Stroke, Prevention
- Trial name
- NCT01924247
- Testing
- Outpatient secondary prevention program, Standard treatment by family physician
- Where
- Switzerland
- Volunteers
- 109 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003634
- Testing
- oregovomab
- Where
- 46 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AltaRex
Loss of Residual Renal Function, Technique Failure in Peritoneal Dialysis
Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients
The primary objective is to analyze peritonitis rate and peritonitis bacteriology as risk factors for loss of residual renal function, technique failure and mortality in chronic kidney disease patients.
- Trial name
- NCT01977716
- Where
- Mexico
- Volunteers
- 350 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Peripheral Arterial Disease, Stenosis
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular…
- Conditions
- Peripheral Arterial Disease, Stenosis, Dissection
- Trial name
- SURF (NCT06539689)
- Testing
- Sperstent® peripheral spot stent system, Everflex® self-expanding peripheral stent system
- Where
- 12 sites in China
- Volunteers
- 240 people
- Sponsor
- FrontAce Scientific Co., Ltd
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of intraperitoneal interleukin-12 in treating patients who have ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00016289
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.